Research Grant Program Expanded to Include Sleep Disorders
Early-career investigators studying narcolepsy and hypersomnia can now apply for funding support.
Updated on Sept. 23, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical companies prioritize funding academic research into complex neurological and psychiatric conditions?
Alkermes plc has updated its annual research grant program to include narcolepsy and idiopathic hypersomnia, marking the ninth cycle of the initiative. The program supports early-career researchers at US medical institutions who are working to advance the understanding of complex neurological conditions.
Why it matters
Expanding these grants may accelerate scientific inquiry into sleep and circadian disorders, providing financial support for investigators exploring new pathways for treatment. By backing early-career research, the initiative aims to foster innovation in fields where further clinical understanding is needed.
Since 2018, the program has awarded approximately $2.9 million to 29 researchers across neuroscience and psychiatry. This ninth annual grant cycle now incorporates narcolepsy type 1 and 2, as well as idiopathic hypersomnia, into its existing research support categories.
The players
Alkermes plc
A biopharmaceutical company focused on the development of innovative medicines for central nervous system diseases.
The details
The program provides grants of up to $100,000 per project to help investigators explore biological, pharmacological, and behavioral aspects of neurological conditions. Applications are vetted by an independent committee of experts in sleep medicine, neurobiology, and psychiatry, ensuring that awarded studies meet rigorous scientific standards. The process begins with a letter of intent followed by a full proposal for those invited to continue.
Timeline
2018: Program inception and start of funding.
September 11, 2026: Start of stage one letter of intent submission.
October 16, 2026: End of stage one submission period.
November 15, 2026: Start of full application phase.
January 5, 2027: End of full application phase.
Health Landscape
This development reflects an ongoing trend in pharmaceutical research, where private funding programs are increasingly widening their scope to address sleep medicine. It represents a pivot toward integrating sleep and circadian disturbances into the broader study of neurological health.
This update may eventually lead to new insights or diagnostic approaches for sleep disorders like narcolepsy. If you are experiencing persistent sleep disturbances, discuss your symptoms with your primary care physician to determine if current diagnostic options are appropriate for your health needs.
The takeaway
The addition of sleep disorders to this research program highlights the growing scientific focus on the role of circadian health in neurological stability. Readers should continue to monitor updates from medical institutions regarding new research findings that could impact future treatment options for chronic sleep conditions.
Further reading
For more on the current status of research into cognitive and neurological conditions, visit Alzheimer’s.
Source note: This article includes information reported by Sleep Review.
Live Poll
Should pharmaceutical companies prioritize funding academic research into complex neurological and psychiatric conditions?
